• TheraVida Inc., of Mountain View, Calif., reported Phase II results showing that lead candidate Tolenix (THVD-201) produced statistically significant improvements in overactive bladder and urge urinary incontinence symptoms over placebo, and patients experienced efficacy similar in magnitude to the maximum dose of active control Detrol (2 mg tolterodine, administered twice daily).